Startups
CORXEL is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world.
Overview
Total raised
$287M
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 23, 2026 | Everest Medicines Accelerates Global Ambitions with Key Acquisitions and Drug Launches | Everest Medicines is reshaping its market footprint. The biopharmaceutical giant secured rights to CARDAMYST™ (etripamil) nasal spray for Greater China. This innovative therapy targets paroxysmal supraventricular tachycardia (PSVT), offerin... |
| Mar 23, 2026 | Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China | SHANGHAI, March 23, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of ... |
| Jan 26, 2026 | Biopharma firm Corxel secures $287m to advance lead product pipeline | Corxel Pharmaceuticals, a clinical-stage biopharmaceutical company with operations in China and the US, has completed a Series D1 funding round at $287 million to support the advancement of its lead product candidate. The Series D1 round at... |
| Jan 26, 2026 | Corxel Pharmaceuticals Raises $287M in Series D1 Funding | Corxel Pharmaceuticals, a Berkeley Heights, NJ-based clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic conditions, raised up to $287M in Series D1 funding. Backers included new investors includi... |
| Jan 22, 2026 | Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug | In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 studies of its oral GLP-1 receptor agonist. Shanghai-headquartered Corxel licens... |
| Corxel |
Reviews 0
FAQ about CORXEL Pharmaceuticals
How much funding has CORXEL Pharmaceuticals raised?
CORXEL Pharmaceuticals has raised $287M in total across 1 funding round.
What has the press written about CORXEL Pharmaceuticals?
Parsers VC has collected 7 articles mentioning CORXEL Pharmaceuticals, among them “Everest Medicines Accelerates Global Ambitions with Key Acquisitions and Drug Launches” (Mar 23, 2026) and “Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater...” (Mar 23, 2026).
Is CORXEL Pharmaceuticals still active?
Yes, CORXEL Pharmaceuticals is active; its latest activity on Parsers VC dates from Jun 8, 2026.